Belimumab, a humanized IgG1 monoclonal antibody which inhibits both soluble and membrane BAFF binding to BAFFR and TACI, was approved for the treatment of SLE [14]–[16]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.